Focused On-demand Library for Hepatocyte growth factor receptor

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
P08581

UPID:
MET_HUMAN

ALTERNATIVE NAMES:
HGF/SF receptor; Proto-oncogene c-Met; Scatter factor receptor; Tyrosine-protein kinase Met

ALTERNATIVE UPACC:
P08581; A1L467; B5A932; E7EQ94; O60366; Q12875; Q9UDX7; Q9UPL8

BACKGROUND:
The Hepatocyte growth factor receptor, integral to signaling pathways such as RAS-ERK and PI3K/AKT, is essential for cell survival, proliferation, and differentiation. It also facilitates the entry of Listeria monocytogenes into cells, showcasing its role in microbial infection. This receptor's activity is critical during wound healing, skeletal muscle development, and hematopoietic cell proliferation.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of the Hepatocyte growth factor receptor could open doors to potential therapeutic strategies. Its involvement in a spectrum of diseases, including autosomal recessive deafness and distal arthrogryposis, highlights its therapeutic potential. Targeting this receptor could lead to innovative treatments for these genetic disorders, enhancing patient care and outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8649 of 8789